Rhythm Pharmaceuticals, Inc. (RYTM) financial statements (2021 and earlier)

Company profile

Business Address 222 BERKELEY STREET
BOSTON, MA 02116
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:173292252148
Cash and cash equivalents101625034
Short-term investments72  114
Other undisclosed cash, cash equivalents, and short-term investments 230203 
Other current assets3411
Other undisclosed current assets6652
Total current assets:182302259151
Noncurrent Assets
Operating lease, right-of-use asset22
Property, plant and equipment3411
Other undisclosed noncurrent assets0000
Total noncurrent assets:5621
TOTAL ASSETS:187309260152
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities1724147
Accounts payable51082
Accrued liabilities131464
Debt 0  
Deferred revenue and credits0
Other undisclosed current liabilities1   
Total current liabilities:1824147
Noncurrent Liabilities
Long-term debt and lease obligation33  
Finance lease, liability33
Liabilities, other than long-term debt  00
Deferred revenue and credits0
Deferred rent credit  0
Total noncurrent liabilities:3300
Total liabilities:2128147
Stockholders' equity
Stockholders' equity attributable to parent167281246145
Common stock0000
Additional paid in capital626606431255
Accumulated other comprehensive income0   
Accumulated deficit(459)(325)(185)(110)
Total stockholders' equity:167281246145
TOTAL LIABILITIES AND EQUITY:187309260152

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Gross profit:   (0)
Operating expenses(137)(146)(78)(32)
Other undisclosed operating income   0
Operating loss:(137)(146)(78)(32)
Nonoperating income (expense)354(1)
Investment income, nonoperating3541
Net loss attributable to parent:(134)(141)(74)(34)
Preferred stock dividends and other adjustments   (4)
Net loss available to common stockholders, diluted:(134)(141)(74)(38)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
Net loss:(134)(141)(74)(34)
Other comprehensive loss (141)  
Comprehensive loss:(134)(281)(74)(34)
Other undisclosed comprehensive income, net of tax, attributable to parent0   
Comprehensive loss, net of tax, attributable to parent:(134)(281)(74)(34)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: